Bayer's third-quarter sales came in a bit higher than anticipated, but the company is girding its loins for a challenging period ahead as generic competition and litigation liabilities bed in. Pharma ...

Bayer has its first regulatory approval for elinzanetant as a non-hormonal treatment for menopausal symptoms – in the UK – as it chases down a rival therapy from Astellas. The Medicines and Healthcare ...

At the end of July, and before the company’s quarterly earnings report coming on Aug. 6, Bayer announced it has allocated an additional $1.37 billion to its efforts around glyphosate litigation. The ...

The initial results from the Bayer Carbon Program are in – and they’re significant. According to Nori, a carbon removal issuing program, registry and marketplace, over 125,000 regenerative tonnes from ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...